Fed­er­al ap­peals court bats back claims No­vo Nordisk’s di­a­betes drug trig­gers pan­cre­at­ic can­cer

A fed­er­al ap­peals court up­held a win for No­vo Nordisk this week, toss­ing out claims that its type 2 di­a­betes drug Vic­toza can cause pan­cre­at­ic can­cer.

The case stems back to mul­ti­dis­trict lit­i­ga­tion from 2013 in which 1,500 plain­tiffs ac­cused sev­er­al phar­ma com­pa­nies of fail­ing to warn of a po­ten­tial link be­tween their type 2 di­a­betes drugs and an in­creased risk of pan­cre­at­ic can­cer — in­clud­ing As­traZeneca’s Byet­ta, No­vo Nordisk’s Vic­toza, and Mer­ck’s Janu­via and Janu­met.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.